Cargando…

Serum-soluble TRAIL levels in patients with severe persistent allergic asthma: Its relation to omalizumab treatment

BACKGROUND: In this study we compare the Omalizumab treatment modality in the dynamics of cell apoptosis regulating molecules in both severe persistent asthma patients who had no other any allergic disease, newly diagnosed patients with allergic asthma, and healthy volunteers. MATERIAL/METHODS: Seve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yalcin, Arzu Didem, Bisgin, Atil, Kargi, Aysegul, Gorczynski, Reginald M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2012
Materias:	Public Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3560751/ https://www.ncbi.nlm.nih.gov/pubmed/22367138 http://dx.doi.org/10.12659/MSM.882504

Ejemplares similares

277 Serum Soluble Trail Levels in Patients With Severe Persistent Allergic Asthma: Its Relation to Omalizumab Treatment
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

278 Total Antioxidant Capacity, Hydrogen Peroxide, Malondialdehyde and Total Nitric Oxide Concentrations in Patients With Severe Persistent Allergic Asthma: Its Relation to Omalizumab Treatment
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Mechanisims of asthma and allergic disease – 1066. Ceruloplasmin oxidase activity in allergic asthma and allergic rhinitis
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

Health outcomes, education, healthcare delivery and quality – 3038: The relation of sTRAIL levels and quality of life in omalizumab using severe persistent allergic asthma patients
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

Health outcomes, education, healthcare delivery and quality – 3052. IL-17, IL-18, TGF-beta and GMCSF levels in patients with allergic asthma: Its relation to omalizumab treatment
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

270 Clinical Experience in Allergic Asthma Patients: Omalizumab with Immunotherapy
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Mechanisims of asthma and allergic disease - 1088. Increased serum strail level in newly diagnosed stave-iv lung adenocarcinoma but not sqamous cell carcinoma, is correlated with age and smoking
por: Kargi, Aysegul, et al.
Publicado: (2013)

233 The Evaluation of Allergen Sensitivity in Allergic Rhinoconjunctivitis and Allergic Asthma Patients in Antalya, Turkey
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Pollen aero allergens and the climate in mediterranean region and allergen sensitivity in allergic rhinoconjunctivitis and allergic asthma patients
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

IL-8, IL-10, TGF-β, and GCSF Levels Were Increased in Severe Persistent Allergic Asthma Patients with the Anti-IgE Treatment
por: Yalcin, Arzu D., et al.
Publicado: (2012)

Environmental and occupational respiratory diseases – 1039. Clinical course and side effects of anti-IgE monoclonal antibody in patients with severe persistent asthma
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

Soluble trail as a marker of efficacy of allergen-specific immunotherapy in patients with allergic rhinoconjunctivitis
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Basic and clinical immunology – 3031. The correlation between serum protemics patterns of sTRAIL and CXCL8 with FDG-PET/CT findings in bevacizumab treated colon cancers
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer
por: Bisgin, Atil, et al.
Publicado: (2012)

Environmental and occupational respiratory diseases – 1062. The climate and aero allergens in Mediterranean region and allergen sensitivity in allergic rhinoconjuctivitis and allergic asthma patients
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

Level of TNF-related apoptosis-inducing-ligand and CXCL8 correlated with 2-[18F]Fluoro-2-deoxy-D-glucose uptake in anti-VEGF treated colon cancers
por: Celik, Betül, et al.
Publicado: (2013)

384 Jessner-kanoff Lymphocytic Infiltrate as a Side Effect of Immunotherapy
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Allergic diseases of the skin and drug allergies – 2027. Successful treatment with intravenous immunoglobulin and prednisolone pulse therapy of toxic epidemal necrolysis and Stevens-Johnson Syndrome
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps
por: Bagnasco, Diego, et al.
Publicado: (2022)

Omalizumab for Severe Asthma: Beyond Allergic Asthma
por: Loureiro, C. C., et al.
Publicado: (2018)

Country-based report: the safety of omalizumab treatment in pregnant patients with asthma
por: GEMİCİOĞLU, Bilun, et al.
Publicado: (2021)

The effects of climate and aero allergens changes in allergic rhinoconjunctivitis and allergic asthma patients in mediterranean region between 2011 and 2012
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

TRAIL Death Receptor-4, Decoy Receptor-1 and Decoy Receptor-2 Expression on CD8(+ )T Cells Correlate with the Disease Severity in Patients with Rheumatoid Arthritis
por: Bisgin, Atil, et al.
Publicado: (2010)

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
por: Snelder, S. M., et al.
Publicado: (2017)

Omalizumab in symptomatic therapy of laryngeal oedema and urticaria attacts in a patient with post operative pulmonary carsinoid tumor
por: Yalcin, Arzu Didem, et al.
Publicado: (2015)

Omalizumab: the evidence for its place in the treatment of allergic asthma
por: McNicholl, Diarmuid M., et al.
Publicado: (2008)

Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma
por: Kotoulas, Serafeim Chrysovalantis, et al.
Publicado: (2022)

Omalizumab and IgE in the Control of Severe Allergic Asthma
por: Gon, Yasuhiro, et al.
Publicado: (2022)

Basic and clinical immunology – 3032. 18FDG-PET/CT findings (SUV-MAX) are correlated with survival in stage-4 squamous cell carcinoma
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

481 Differences in Humoral and Cellular Immunity in Young and Old Individuals
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Omalizumab in the management of patients with allergic (IgE-mediated) asthma
por: Sandström, Thomas
Publicado: (2009)

Omalizumab for severe allergic asthma: a life changing drug?
por: Mesonjesi, Eris, et al.
Publicado: (2015)

Omalizumab as add-on therapy in patients with asthma and allergic bronchopulmonary aspergillosis
por: da Cunha, Fernanda Sales, et al.
Publicado: (2018)

Levofloxacin Induced Toxic Epidermal Necrolysis: Successful Therapy with Omalizumab (Anti-IgE) and Pulse Prednisolone
por: Uzun, Rusen, et al.
Publicado: (2016)

Vitamin D serum levels in allergic rhinitis
por: Kose, Sukran, et al.
Publicado: (2015)

Omalizumab in patients with severe asthma and persistent sputum eosinophilia
por: Mukherjee, Manali, et al.
Publicado: (2019)

426 The Evaluation of Allergen Sensitivity in Food Allergy Patients in Antalya, Turkey
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Omalizumab in Children with Severe Allergic Asthma: The Italian Real-Life Experience
por: Licari, Amelia, et al.
Publicado: (2017)

Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
por: Zafari, Zafar, et al.
Publicado: (2018)

Omalizumab and unmet needs in severe asthma and allergic comorbidities in Japanese children
por: Nishima, Sankei, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_oi69isk151igpslmq5ulqglljk